Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A phase 3 randomized, double-blind, placebo- and active-controlled, multi-center, parallel group study to evaluate the safety and efficacy of darusentan in subjects with resistant hypertension receiving combination therapy with three or more antihypertensive drugs, including a diuretic, as compared to guanfacine or placebo (protocol DAR-312)

X
Trial Profile

A phase 3 randomized, double-blind, placebo- and active-controlled, multi-center, parallel group study to evaluate the safety and efficacy of darusentan in subjects with resistant hypertension receiving combination therapy with three or more antihypertensive drugs, including a diuretic, as compared to guanfacine or placebo (protocol DAR-312)

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 29 Dec 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Darusentan (Primary) ; Guanfacine
  • Indications Resistant hypertension
  • Focus Registrational; Therapeutic Use
  • Acronyms DORADO-AC
  • Sponsors Gilead Sciences
  • Most Recent Events

    • 03 Jul 2012 Additional locations added as reported by European Clinical Trials Database record.
    • 19 Mar 2010 Status of extension study changed from active, no longer recruiting to discontinued, as reported by ClinicalTrials.gov.
    • 15 Dec 2009 Status changed from completed to discontinued as reported in Gilead's media release.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top